CompletedPHASE2, PHASE3NCT00490620

Study of Combivir for Patients With Primary Biliary Cirrhosis

Studying Primary biliary cholangitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Alberta
Principal Investigator: Andrew L Mason, MBBS MRCPI
University of Alberta
Intervention: Combination antiviral therapy(drug)
Enrollment: 59 target
Eligibility: 18-75 years · All sexes
Timeline: 2004 – 2007

Study locations (5)

Mayo Clinic, Rochester, Minnesota, United States
St Louis University, St Louis, Missouri, United States
University of Alberta, Edmonton, Alberta, Canada
University of Montreal, Montreal, Quebec, Canada
University of Birmingham, Birmingham, England, United Kingdom

Collaborators

GlaxoSmithKline · Axcan Pharma

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00490620 on ClinicalTrials.gov

Other trials for Primary biliary cholangitis

Additional recruiting or active studies for the same condition.

See all trials for Primary biliary cholangitis →

← Back to all trials